Advertisement

Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥60 years with HL

Jonathan W. Friedberg, Andres Forero-Torres, Rodolfo E. Bordoni, Vivian J.M. Cline, Dipti Patel Donnelly, Patrick J. Flynn, Gregg Olsen, Robert Chen, Abraham Fong, Yinghui Wang and Christopher A. Yasenchak

Article Information

PubMed 

Print ISSN 
Online ISSN 
History 
  • Submitted June 13, 2017
  • Accepted October 3, 2017
  • Published online October 16, 2017.


Contributors 
  • Jonathan W. Friedberg, 1 University of Rochester Wilmot Cancer Institute, Rochester, NY, United States;
  • Andres Forero-Torres, 2 University of Alabama at Birmingham, Birmingham, AL, United States;
  • Rodolfo E. Bordoni, 3 Georgia Cancer Specialists, Marietta, GA, United States;
  • Vivian J.M. Cline, 4 Texas Oncology-Round Rock Seton Williamson, Round Rock, TX, United States;
  • Dipti Patel Donnelly, 5 Virginia Cancer Specialists, Fairfax, VA, United States;
  • Patrick J. Flynn, 6 Minnesota Oncology, Woodbury, MN, United States;
  • Gregg Olsen, 7 Providence Saint Joseph Medical Center, Burbank, CA, United States;
  • Robert Chen, 8 City of Hope Medical Center, Duarte, CA, United States;
  • Abraham Fong, 9 Seattle Genetics, Inc., Bothell, WA, United States;
  • Yinghui Wang, 9 Seattle Genetics, Inc., Bothell, WA, United States;
  • Christopher A. Yasenchak, 10 Willamette Valley Cancer Institute and Research Center/US Oncology Research, Eugene, OR, United States

Altmetric.com Statistics

The Altmetric score is a weighted count of online attention designed to reflect the volume and reach of online engagement surrounding an individual research output